Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: a modified cohort event monitoring study in public health facilities in Ghana and Uganda

被引:11
|
作者
Ampadu, H. Hilda [1 ,2 ]
Asante, Kwaku Poku [3 ]
Bosomprah, Samuel [4 ]
Akakpo, Samantha [5 ]
Hugo, Pierre [5 ]
Gardarsdottir, Helga [2 ,6 ]
Leufkens, Hubert G. M. [2 ]
Kajungu, Dan [7 ]
Dodoo, Alexander N. O. [1 ]
机构
[1] African Collaborating Ctr Pharmacovigilance & Sur, Accra, Ghana
[2] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Fac Sci, Utrecht, Netherlands
[3] Kintampo Hlth Res Ctr, Ghana Hlth Serv, Kintampo, Ghana
[4] Univ Ghana, Sch Publ Hlth, Dept Biostat, Accra, Ghana
[5] Med Malaria Venture, Geneva, Switzerland
[6] Univ Med Ctr Utrecht, Div Lab & Pharm, Dept Clin Pharm, Utrecht, Netherlands
[7] Makerere Univ, Ctr Hlth & Populat Res MUCHAP, IMH DSS, Kampala, Uganda
关键词
Prescription; Malaria; Injectable artesunate; Injectable artemether; Injectable quinine; SEVERE FALCIPARUM-MALARIA; CHILDREN; ARTESUNATE; QUININE;
D O I
10.1186/s12936-019-2670-9
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
BackgroundInjectable artesunate (AS) is the World Health Organization (WHO) recommended medication for the treatment of severe malaria followed with an oral artemisinin-based combination therapy (ACT). There are few studies indicating how physicians prescribe injectable AS, injectable quinine (Q) or injectable artemether (AR) and ACT for severe malaria. This study was undertaken to evaluate prescription compliance to the WHO recommendation in 8 public health facilities in Ghana and Uganda. This was a modified cohort event monitoring study involving patients who were administered with injectable anti-malarial for treatment of presumed or confirmed severe malaria. Patients prescribed at least one dose of injectable artesunate, artemether or quinine qualified to enrol in the study. Patients were recruited at inpatient facilities and followed up in the hospital, by phone or at home. Following WHO recommendations, patients are to be prescribed 3 doses of injectable AS, Q or AR for at least 24h followed with oral ACT. Compliance rate was estimated as the number of patient prescriptions that met the WHO recommendation for treatment of severe malaria divided by the total number of patients who completed the study by end of follow up. Log-binomial regression model was used to identify predictors for compliance. Based on the literature and limitations of available data from the patients' record, the diagnosis results, age, gender, weight, and country were considered as potential predictors of prescriber adherence to the WHO recommendations.ResultsA total of 1191 patients completed the study, of which 93% were prescribed injectable AS, 3.1% (injectable AR or Q) with 32.5% prescribed follow-on oral ACT and 26% on concomitant antibiotics. 391 (32.8%) were in Ghana and 800 (67.2%) in Uganda. There were 582 (48.9%) women. The median age was 3.9years (IQR=2, 9) and median weight was 13kg (IQR=10, 20). Of the 1191 patients, 329 of the prescriptions complied with the WHO recommendation (compliance rate=27.6%; 95% CI=[25.2, 30.2]). Diagnostic results (Adjusted prevalence ratio (aPR)=4.56; 95%=[3.42, 6.08]; p<0.0001) and weight (20+kg vs<10kg: aPR=0.65; 95%=[0.44, 0.96]; p=0.015) were identified as factors independently associated with compliance.ConclusionInjectable AS is the most commonly prescribed medicine in the management of severe malaria in Ghana and Uganda. However, adherence to the WHO recommendation of at least 3 doses of injectable anti-malarial in 24h followed by a full course of ACT is low, at less than 30%.
引用
收藏
页数:8
相关论文
共 5 条
  • [1] Prescribing patterns and compliance with World Health Organization recommendations for the management of severe malaria: a modified cohort event monitoring study in public health facilities in Ghana and Uganda
    H. Hilda Ampadu
    Kwaku Poku Asante
    Samuel Bosomprah
    Samantha Akakpo
    Pierre Hugo
    Helga Gardarsdottir
    Hubert G. M. Leufkens
    Dan Kajungu
    Alexander N. O. Dodoo
    Malaria Journal, 18
  • [2] Safety Experience During Real-World Use of Injectable Artesunate in Public Health Facilities in Ghana and Uganda: Outcomes of a Modified Cohort Event Monitoring Study (CEMISA)
    Ampadu, H. Hilda
    Dodoo, Alexander N. O.
    Bosomprah, Samuel
    Akakpo, Samantha
    Hugo, Pierre
    Gardarsdottir, Helga
    Leufkens, H. G. M.
    Kajungu, Dan
    Asante, Kwaku Poku
    DRUG SAFETY, 2018, 41 (09) : 871 - 880
  • [3] Prescription patterns and compliance with World Health Organization recommendations for the management of uncomplicated and severe malaria: A prospective, real-world study in sub-Saharan Africa
    Baraka, Vito
    Nhama, Abel
    Aide, Pedro
    Bassat, Quique
    David, Agatha
    Gesase, Samwel
    Gwasupika, Jonathan
    Hachizovu, Sebastian
    Makenga, Geofrey
    Ntizimira, Christian Ruchaho
    Obunge, Orikomaba
    Tshefu, Kitoto Antoinette
    Cousin, Marc
    Otsyula, Nekoye
    Pathan, Rashidkhan
    Risterucci, Celine
    Su, Guoqin
    Manyando, Christine
    MALARIA JOURNAL, 2023, 22 (01)
  • [4] Prescription patterns and compliance with World Health Organization recommendations for the management of uncomplicated and severe malaria: A prospective, real-world study in sub-Saharan Africa
    Vito Baraka
    Abel Nhama
    Pedro Aide
    Quique Bassat
    Agatha David
    Samwel Gesase
    Jonathan Gwasupika
    Sebastian Hachizovu
    Geofrey Makenga
    Christian Ruchaho Ntizimira
    Orikomaba Obunge
    Kitoto Antoinette Tshefu
    Marc Cousin
    Nekoye Otsyula
    Rashidkhan Pathan
    Céline Risterucci
    Guoqin Su
    Christine Manyando
    Malaria Journal, 22
  • [5] Safety Profile of Artemether-Lumefantrine: A Cohort Event Monitoring Study in Public Health Facilities in Tanzania
    Alambo K. Mssusa
    Adam M. Fimbo
    Alex F. Nkayamba
    Henry F. Irunde
    Hiiti B. Sillo
    Danstan H. Shewiyo
    Geraldine Hill
    Omary M. Minzi
    Clinical Drug Investigation, 2016, 36 : 401 - 411